Data / Drug companies / Meitheal Pharmaceuticals Inc.
Meitheal Pharmaceuticals Inc.: 211 products in the FDA NDC directory, labeler code 71288
Meitheal Pharmaceuticals Inc. (labeler code 71288) lists 211 products in the FDA National Drug Code Directory, covering 88 finished drugs by generic name. By type: 211 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 19, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 71288
- Products in commercial distribution
- 211
- Packages
- 235
- Finished drugs by generic name
- 88
- Prescription products
- 211
- Over the counter products
- 0
- Flagged as original packager
- 196 of 196 products that carry the flag
- Started marketing in the last 12 months
- 14
- Products with a marketing end date set
- 8
- Earliest marketing start
- November 29, 2005
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 200 | 94.8% |
| Biologics (BLA) | 7 | 3.3% |
| New drug applications (NDA) | 4 | 1.9% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 211 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 75 | 35.5% |
| Injection | 54 | 25.6% |
| Injection, powder, lyophilized, for solution | 49 | 23.2% |
| Injection, powder, for solution | 12 | 5.7% |
| Injection, solution, concentrate | 9 | 4.3% |
| Kit | 4 | 1.9% |
| Injection, emulsion | 3 | 1.4% |
| Powder, for solution | 2 | 0.9% |
| Injection, powder, lyophilized, for suspension | 1 | 0.5% |
| Tablet, coated | 1 | 0.5% |
| Solution | 1 | 0.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Eribulin mesylate | 71288-173 | Injection | Generic drugs (ANDA) | October 19, 2026 |
| Yusimry | 71288-818 | Injection, solution | Biologics (BLA) | September 25, 2026 |
| Yusimry | 71288-817 | Injection, solution | Biologics (BLA) | September 25, 2026 |
| Thiamine Hydrochloride | 71288-804 | Injection, solution | Generic drugs (ANDA) | September 25, 2026 |
| Insulin Diluting Medium for Garzulys | 71288-909 | Injection, solution | Biologics (BLA) | July 24, 2026 |
| Garzulys | 71288-904 | Injection, solution | Biologics (BLA) | July 24, 2026 |
| Garzulys | 71288-903 | Injection, solution | Biologics (BLA) | July 24, 2026 |
| Tigecycline | 71288-019 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 1, 2026 |
| Desmopressin acetate | 71288-441 | Injection | Generic drugs (ANDA) | February 13, 2026 |
| Desmopressin acetate | 71288-440 | Injection | Generic drugs (ANDA) | February 13, 2026 |
| Propofol | 71288-731 | Injection, emulsion | Generic drugs (ANDA) | December 2, 2025 |
| Propofol | 71288-730 | Injection, emulsion | Generic drugs (ANDA) | December 2, 2025 |
| Propofol | 71288-729 | Injection, emulsion | Generic drugs (ANDA) | December 2, 2025 |
| Dalbavancin | 71288-034 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | November 26, 2025 |
| Contepo | 71288-035 | Injection, powder, for solution | New drug applications (NDA) | October 22, 2025 |
| Nicardipine hydrochloride | 71288-204 | Injection, solution | Generic drugs (ANDA) | August 20, 2025 |
| Heparin Sodium | 71288-451 | Injection | Generic drugs (ANDA) | July 2, 2025 |
| Heparin Sodium | 71288-450 | Injection | Generic drugs (ANDA) | July 2, 2025 |
| Heparin Sodium | 71288-449 | Injection | Generic drugs (ANDA) | July 2, 2025 |
| Vecuronium Bromide | 71288-745 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 1, 2025 |
| Vecuronium Bromide | 71288-744 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 1, 2025 |
| Hydralazine hydrochloride | 71288-205 | Injection | Generic drugs (ANDA) | June 2, 2025 |
| Idarubicin Hydrochloride | 71288-186 | Injection, solution | Generic drugs (ANDA) | June 1, 2025 |
| Idarubicin Hydrochloride | 71288-185 | Injection, solution | Generic drugs (ANDA) | June 1, 2025 |
| Idarubicin Hydrochloride | 71288-184 | Injection, solution | Generic drugs (ANDA) | June 1, 2025 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.